Patents by Inventor Robert Polakiewicz

Robert Polakiewicz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7906297
    Abstract: The invention discloses two novel phosphorylation sites in human ATR kinase, serine 428 (Ser428) and serine 2317 (Ser2317) respectively, and provides reagents, including antibodies and AQUA peptides, that selectively bind to and/or detect ATR only when phosphorylated at one or more of these respective sites, but do not bind to ATR when not phosphorylated at these respective sites. Also provided are methods for determining the phosphorylation of ATR kinase in a biological sample, by using a detectable reagent that binds to ATR only when phosphorylated at Ser428 and/or Ser2317. Kits comprising the ATR (Ser428, Ser2317)-specific reagents of the invention are also provided.
    Type: Grant
    Filed: July 17, 2006
    Date of Patent: March 15, 2011
    Assignee: Cell Signaling Technology, Inc.
    Inventors: Mark Livingstone, Hong Ruan, Robert Polakiewicz
  • Patent number: 7807789
    Abstract: The invention discloses 168 novel phosphorylation sites identified in signal transduction proteins and pathways downstream of, and including, EGFR kinase, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Actin Binding proteins, Adaptor/Scaffold proteins, Calcium-Binding Proteins, Cell Cycle Regulation proteins, Cytoskeletal proteins, DNA Binding and Replication Proteins, GTPase Activating proteins, Guanine Nucleotide Exchange Factor proteins, Lipid Kinases, Receptor Tyrosine Kinases, Receptor Tyrosine Kinase ligands, Protein Kinases, Receptor and Protein Phosphatases, Transcription Factor proteins, Tumor Suppressor proteins, and Vesicle proteins.
    Type: Grant
    Filed: June 21, 2007
    Date of Patent: October 5, 2010
    Assignee: Cell Signaling Technology, Inc.
    Inventors: Ailan Guo, Kimberly Lee, Klarisa Rikova, Charles Farnsworth, Albrecht Moritz, Yu Li, Robert Polakiewicz
  • Publication number: 20090197269
    Abstract: In accordance with the invention, a novel gene translocation, (3p21, 5q33), in human myelogenous leukemia (AML) that results in a fusion protein combining part of RNA Binding Protein-6 (RBM6) with Macrophage Colony Stimulating Factor-1 Receptor (CSF1R) kinase has now been identified. The RBM6-CSF1R fusion protein and truncated CSF1R kinase itself, which both retain CSF1R tyrosine kinase activity, were confirmed to drive the proliferation and survival of acute megakaryoblastic leukemia (AML-M7). The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant CSF1R kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides.
    Type: Application
    Filed: June 20, 2008
    Publication date: August 6, 2009
    Inventors: Ting-Lei Gu, Valerie Goss, Robert Polakiewicz, Brian Druker, Denise Walters
  • Publication number: 20080108795
    Abstract: The invention discloses 168 novel phosphorylation sites identified in signal transduction proteins and pathways downstream of, and including, EGFR kinase, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Actin Binding proteins, Adaptor/Scaffold proteins, Calcium-Binding Proteins, Cell Cycle Regulation proteins, Cytoskeletal proteins, DNA Binding and Replication Proteins, GTPase Activating proteins, Guanine Nucleotide Exchange Factor proteins, Lipid Kinases, Receptor Tyrosine Kinases, Receptor Tyrosine Kinase ligands, Protein Kinases, Receptor and Protein Phosphatases, Transcription Factor proteins, Tumor Suppressor proteins, and Vesicle proteins.
    Type: Application
    Filed: June 21, 2007
    Publication date: May 8, 2008
    Inventors: Ailan Guo, Kimberly Lee, Klarisa Rikova, Charles Farnsworth, Albrecht Moritz, Yu Li, Robert Polakiewicz
  • Publication number: 20070166764
    Abstract: The invention discloses two novel phosphorylation sites in human ATR kinase, serine 428 (Ser428) and serine 2317 (Ser2317) respectively, and provides reagents, including antibodies and AQUA peptides, that selectively bind to and/or detect ATR only when phosphorylated at one or more of these respective sites, but do not bind to ATR when not phosphorylated at these respective sites. Also provided are methods for determining the phosphorylation of ATR kinase in a biological sample, by using a detectable reagent that binds to ATR only when phosphorylated at Ser428 and/or Ser2317. Kits comprising the ATR (Ser428, Ser2317)-specific reagents of the invention are also provided.
    Type: Application
    Filed: July 17, 2006
    Publication date: July 19, 2007
    Inventors: Mark Livingstone, Hong Ruan, Robert Polakiewicz